Option chain shows key data for Adamant DRI's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Adamant DRI.

Adamant DRI (OTC:ADMG) Stock, Option Chain

Adamant DRI Processing and Minerals Group is a shell company.

News

Intraday Update

Markets

Movers

Trading Ideas

AAVMY

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

ACHFF

ACRX

ADMG

ANGO

AOXY

ASPCF

ATRO

ATROB

AWLCF

BIOIF

BLUBF

BMMJ

BNFT

BORR

BSBR

BSET

BUDFF

CDEV

CEIX

CJPRY

CNNB

CPNFF

CRWG

CTRM

CULP

CVGI

CYBQY

DKAM

DKGR

DLRYF

DMCHY

DYLLF

ECOL

EJPRY

EMLL

ENBL

ETCC

ETFM

GEIN

GFGSF

GLYE

GNMK

GTCH

HAIPF

HNRG

IMAC

INND

ITEX

JAMN

JAPSY

KEQU

KNCAF

KOTMY

LATF

LIVE

LNTH

LONE

LPRRF

LQDT

MAHLY

MHVYF

MLMZF

MSPC

METALLIS RESOURCES INC by Metallis Resources, Inc.

MTLFF

MZDAF

NAKD

NBLX

NINOY

NMCI

NSANF

NSANY

NTGR

NZRFF

OMVKY

Stocks That Hit 52-Week Lows On Tuesday

ADAMANT DRI PRCNG &MNRLS by Adamant DRI Processing and Minerals Group

Adamant DRI Processing and Minerals Group

Market-Moving Exclusives

Exclusives

VMAR

EXCLUSIVE: Vision Marine Tells Benzinga Co. Partners With A Major Pontoon Manufacturer To Produce Cutting-Edge Electric Pontoons

Key UAV stakeholders assembled with government officials to confer on U.S. drone technology matters&nbsp;
WICHITA, Kan., Nov. 18, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KGUFm66kiG7Wu-BxEHrptElGcqCBoyvXMDQjhyieKwrX-CJp2C6adUVBUu6kx4jYTZeI3sjTp7DgzoC1I5iFytJDusMr6DUI4cwpKIyL5kQ=">AgEagle Aerial Systems Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>)&nbsp;a leading provider of best-in-class unmanned aerial systems (UAS), sensors and software solutions for customers worldwide in the commercial and government verticals, announces the company recently attended the White House by invitation to engage in strategic discussions regarding the future of commercial unmanned aerial vehicles (UAVs).
The meeting assembled key stakeholders from the UAV industry along with government officials from the National Security Council and National Economic Council to explore a variety of issues including supply chain security, manufacturing, and policies related to beyond visual line of sight operations (BVLOS) in U.S. airspace.

UAVS

Ageagle Aerial Systems Invited To The White House For Key Discussions On Commercial Unmanned Aerial Vehicles

WIIM

NGNE

Neurgogene shares are trading lower after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett syndrome patient.

Loop Capital analyst Ananda Barush initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announces Price Target of $30.

Price Target

Initiation

Analyst Ratings

INGM

Loop Capital Initiates Coverage On Ingram Micro Holding with Buy Rating, Announces Price Target of $30

Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone
INVINCIBLE-3 Study is recruiting and expected to enroll 333 patients with leiomyosarcoma, liposarcoma and undeferential pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Canada, Europe and Australia
SHELTON, Conn., Nov. 18, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4303989-1&amp;h=289952651&amp;u=https%3A%2F%2Fintensitytherapeutics.com%2F&amp;a=Intensity+Therapeutics%2C+Inc.">Intensity Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that Christian F. Meyer M.D., Ph.D., Assistant Professor of Oncology and lead medical oncologist for adult sarcoma patients at Johns Hopkins University's Sidney Kimmel Cancer Center, presented final safety and efficacy data from the Company's Phase 1/2 clinical trial of INT230-6&nbsp;that was used as a monotherapy in patients with relapsed, refractory, and metastatic sarcomas, along with an overview of the Company's ongoing INVINCIBLE-3 Study design (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4303989-1&amp;h=2975858526&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4227864-1%26h%3D466760238%26u%3Dhttps%253A%252F%252Fwww.clinicaltrials.gov%252Fstudy%252FNCT06263231%253Fterm%253DINT230-6%2526rank%253D3%26a%3DNCT06263231&amp;a=NCT06263231">NCT06263231</a>). Dr. Meyer shared the information during an oral podium presentation in a late-breaking session at the 2024 Connective Tissue Oncology Society ("CTOS") on November 16, 2024, at 9 AM PST. The abstract's lead author was Albiruni Razak, MB BCh, BM BCh, Clinician Investigator, Princess Margaret Cancer Centre at the University Hospital Network in Toronto, Ontario, Canada. Both Drs. Razak and Meyer, enrolled patients in the Phase 1/2 clinical trial. This year's annual CTOS conference was held in San Diego from November 13 to 16, 2024 at the Grand Hyatt.

Biotech

General

INTS

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data In Sarcoma And An Overview Of Its Ongoing Global Randomized Phase 3 Sarcoma Trial In A Late-Breaking Session At The 2024 Annual Connective Tissue Oncology Society Meeting; Phase 1/2 Data Showed A Median Overall Survival Of 21.3 Months Versus A Synthetic Control Of 6.7 Months, An Increase In T-Cell Activation, And Favorable Safety Profile For Patients Receiving INT230-6 Alone

SolarEdge Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NYSE">SEDG</a>) short percent of float has risen 13.92% since its last report. The company recently reported that it has 19.16 million shares sold short, which is 39.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.51 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>SolarEdge Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731935723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SolarEdge Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing SolarEdge Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SolarEdge Technologies's peer group average for short interest as a percentage of float is 6.38%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SEDG

How Is The Market Feeling About SolarEdge Technologies?

Regeneron Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NYSE">REGN</a>) short percent of float has risen 8.54% since its last report. The company recently reported that it has 1.85 million shares sold short, which is 1.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Regeneron Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731935718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Regeneron Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Regeneron Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

REGN

Peering Into Regeneron Pharmaceuticals's Recent Short Interest

Phunware's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NYSE">PHUN</a>) short percent of float has risen 12.5% since its last report. The company recently reported that it has 1.43 million shares sold short, which is 12.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Phunware Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731935713_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Phunware has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Phunware's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Phunware's peer group average for short interest as a percentage of float is 5.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

PHUN

How Is The Market Feeling About Phunware?

Calidi Biotherapeutics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, presented data at the International Oncolytic Virotherapy Conference (IOVC) and the Society for Immunotherapy of Cancer (SITC) Annual Meeting to support the targeted capabilities of its proprietary RTNova&#x2122; systemic enveloped virotherapy technology. This data supports the potential use of RTNova to target every metastatic site in multiple oncology indications including metastatic lung cancer.
RTNova is uniquely designed to overcome key challenges in systemic virotherapy, including rapid immune clearance and limited therapeutic targeting. By incorporating enveloped technology into its tumor-selective vaccinia virus platform, RTNova now has the potential to target multiple metastatic tumor sites, killing and transforming, not one, but potentially all tumor microenvironments in the body. Calidi's enveloped virotherapies demonstrated robust therapeutic potential as a monotherapy and as a viral vector, allowing future expansion of functionality to support delivery of therapeutic gene or medicine payloads into all tumor sites.

CLDI

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology To Target Metastatic Lung Cancer

Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication and discussion of a manuscript "Oral LPCN 1148 Improves Sarcopenia and Hepatic Encephalopathy in Male Patients with Cirrhosis: a randomized, placebo-controlled Phase 2 trial" in the journal Hepatology and discussion at The Liver Meeting (AASLD) 2024 Editor's Cut: Clinical Study Session held on November 16, 2024. LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action for overt hepatic encephalopathy and sarcopenia indications. A copy of the publication can be accessed <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4304805-1&amp;h=1195872298&amp;u=https%3A%2F%2Fjournals.lww.com%2Fhep%2Fabstract%2F9900%2Foral_lpcn_1148_improves_sarcopenia_and_hepatic.1074.aspx&amp;a=here">here</a>.
The publication features the results from a Phase 2 proof-of-concept clinical trial (LPCN 1148-21-001) that evaluated LPCN 1148 in men with cirrhosis and sarcopenia awaiting liver transplantation. The trial was conducted in two stages. Stage 1 was double blind, placebo-controlled with participants randomized 1:1, to receive either oral LPCN 1148 or placebo. This was followed by Stage 2, a 28-week single-arm open label extension. The publication reports the analyses from the Stage 1 readout.
The results at 24 weeks showed that LPCN 1148 therapy resulted in a significant improvement in sarcopenia when compared with placebo. Furthermore, despite most participants already on background therapies for HE, participants receiving LPCN 1148 also experienced significantly fewer episodes of overt hepatic&nbsp;encephalopathy (OHE) compared to those on placebo. Additional beneficial effects of LPCN 1148, including improved muscle quality, hemoglobin, and patient reported symptom improvement are also covered in the manuscript.
The publication was discussed at The Liver Meeting during 'The Editors Cut: Clinical Studies' session. This session critically discusses the most notable, influential, cutting edge, game changing clinical research papers published during the past year.

LPCN

Lipocine Announces The Publication And Discussion Of A Manuscript "Oral LPCN 1148 Improves Sarcopenia And Hepatic Encephalopathy In Male Patients With Cirrhosis: A Randomized, Placebo-controlled Phase 2 Trial" In The Journal Hepatology And Discussion At The Liver Meeting 2024 Editor's Cut

Actinium Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 24.49 percent increase over losses of $(0.49) per share from the same period last year.

Earnings

ATNM

Actinium Pharmaceuticals Q3 EPS $(0.37) Misses $(0.30) Estimate

ACRS

Aclaris Therapeutics Secures $80M Through Private Placement Of 35.56M Shares At $2.25 Per Share; Funds To Support Pipeline Development And General Corporate Purposes

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintains Assured Guaranty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGO#NYSE">AGO</a>) with a Outperform and raises the price target from $92 to $105.

Keefe, Bruyette & Woods Maintains Outperform on Assured Guaranty, Raises Price Target to $105

RVTY

Revvity Announces Investor Day For Nov. 21 And Updates Organizational Structure; Applied Genomics To Merge Into Life Sciences Solutions In Fiscal 2025, Streamlining Operations And Enhancing Customer Focus Across Key Markets

<a href="https://www.globenewswire.com/Tracker?data=-QW-u4gy0j6s3TaJWTrbeEe73NtGe4Tb55n18CRSdTy1J1hwkSUeWC5jkGG_zp9W2OFObQE_HpO5giP-JQxw1zhzTUXU5Uep8_RsrR9dBIs=">Genius Group Limited</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that it had completed the purchase of 110 Bitcoin for $10 million, at an average price of $90,932 per Bitcoin.
The purchase follows the Company's announcement on November 12 of its "Bitcoin-first" strategy in which it is committing 90% or more of its current and future reserves to be held in Bitcoin, with an initial target of $120 million in Bitcoin. The $10 million of Bitcoin purchased since the announcement is the first of ongoing purchases the Company intends to make towards its target.

Genius Group Launches Bitcoin Treasury With Purchase Of 110 Bitcoin For $10M

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion For Worldwide Rights (Excluding Greater China) To BSI-045B

<ul>
<li>Published in the Journal of Clinical Anesthesia, results from the two-phase, 250 patient pilot study show clinicians found a majority (82%) of the alarms from the wireless and wearable Portrait Mobile monitoring solution to be informative or useful to optimize patient care in medical-surgical units.1</li>
<li>Study findings suggest that continuous monitoring helps provide critical information to clinicians, enabling them to intervene effectively before a patient deteriorates.</li>
<li>Undetected patient deterioration, particularly post-surgery, can lead to hazardous yet preventable consequences, with 30-day mortality after surgery representing the third leading cause of death globally.2</li>
</ul>
GE HealthCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) today announced the publication of data from a two-phase pilot study conducted with Cleveland Clinic in the peer-reviewed <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0952818024002903%3Fvia%253Dihub&amp;esheet=54153539&amp;newsitemid=20241118649936&amp;lan=en-US&amp;anchor=Journal+of+Clinical+Anesthesia&amp;index=1&amp;md5=3882fc8ec1955dd12edab44322fe51f9">Journal of Clinical Anesthesia</a>, highlighting performance of the wireless and wearable Portrait&#x2122; Mobile monitoring solution in the post-surgical ward environment.
With published alarm rates from critical care and cardiac telemetry units that number in the hundreds per bed per day, healthcare systems may be concerned with alarm management in lower acuity settings.3,4 The results from this study highlight the potential of the wireless and wearable Portrait Mobile monitoring solution to provide meaningful alarms for clinicians and help encourage clinical intervention while minimizing alarm fatigue.1
The COSMOS (Continuous Ward Monitoring with the GE HealthCare Portrait Mobile Monitoring Solution) pilot study compares continuous monitoring with Portrait Mobile to routine intermittent vital signs assessment only. Key findings include:
<ul>
<li>In the Portrait Mobile group, there was an average of less than three alarms per patient per day.</li>
<li>Clinicians found a majority (82%) of the Portrait Mobile alarms to be informative or useful.</li>
<li>Portrait Mobile alarms informed clinical decisions, and the most common nursing intervention was theinitiation of oxygen therapy or increase in the concentration of oxygen administered to a patient. Clinicians were prompted to supplement oxygen in about 60% more patients assigned to the Portrait Mobile group compared to patients with intermittent monitoring only (49 vs. 33, respectively).
<ul>
<li>In the Portrait Mobile group, continuous monitoring and alerts led to clinical interventions that reduced vital sign abnormalities by approximately 25%.</li>
</ul>
</li>
</ul>

GEHC

GE HealthCare Announces The Publication Of Data From A Two-Phase Pilot Study Conducted With Cleveland Clinic In The Peer-Reviewed Journal Of Clinical Anesthesia, Highlighting Performance Of The Wireless And Wearable Portrait Mobile Monitoring Solution In The Post-Surgical Ward Environment

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.0500</td>
<td align="right">2.61</td>
<td align="right">1.22</td>
<td>1.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">95.1000</td>
<td align="right">0.37</td>
<td align="right">0.39</td>
<td>23.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">49.9100</td>
<td align="right">0.04</td>
<td align="right">0.08</td>
<td>80.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.0103</td>
<td align="right">0.05</td>
<td align="right">0.06</td>
<td>28.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.82</td>
<td align="right">-0.16</td>
<td align="right">-0.38</td>
<td>841</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">79.11</td>
<td align="right">-0.14</td>
<td align="right">-0.18</td>
<td>9.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">138.90</td>
<td align="right">-0.21</td>
<td align="right">-0.16</td>
<td>437</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">141.65</td>
<td align="right">-0.19</td>
<td align="right">-0.14</td>
<td>16.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">228.70</td>
<td align="right">-0.01</td>
<td align="right">-0.01</td>
<td>21.2K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For November 18, 2024

CTNM

Contineum Therapeutics Announces FDA Authorization Of Its IND Application For PIPE-791

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith upgrades MBIA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBI#NYSE">MBI</a>) from Market Perform to Outperform and raises the price target from $6.5 to $9.

Upgrades

Keefe, Bruyette & Woods Upgrades MBIA to Outperform, Raises Price Target to $9

Adamant DRI

Comments

Adamant DRI

Adamant DRI (ADMG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga